---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-008900"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:43:39.240559+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tonix TNX-801 vaccine data: 100,000-fold less virulent, s.c. route protective

## Summary
- TNX-801 is up to 100,000-fold less virulent than licensed vaccinia in interferon receptor knockout mice.
- Subcutaneous administration yields equivalent protection to percutaneous route; company plans s.c. product first.
- Single dose protected all vaccinated macaques from lethal Clade I mpox challenge without lesions.
- Rabbit models remained fully protected for 14 months post single dose.
- Company to advance TNX-801 into clinic via subcutaneous delivery for mpox and smallpox prevention.

## SEC filing metadata
- accession: 0001999371-25-008900
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125008900/0001999371-25-008900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125008900/tonix-8k_071025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-008900
- JSON: https://secwatch.observer/filing/0001999371-25-008900.json
- Plain text: https://secwatch.observer/filing/0001999371-25-008900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.